Acute Myeloid Leukemia Market Size, Share, Forecast & Trends Analysis by Therapy Class, Mutation Target, Line of Therapy, Patient Fitness, Route of Administration, Treatment Setting, End User, and Geography - Global Forecast to 2036

The global acute myeloid leukemia (AML) market was valued at USD 4.35 billion in 2025. It is estimated at USD 4.90 billion in 2026 and is expected to reach USD 11.81 billion by 2036, growing at a CAGR of 9.2% over the 2026-2036 forecast period. This report assesses epidemiology, molecular subtypes, treatment pathways, diagnostics and measurable residual disease (MRD) testing, the pipeline, pricing and reimbursement, regulation, and competition.

The study covers drugs used to treat AML across induction, consolidation, maintenance, and relapsed or refractory settings. It includes targeted therapy (menin inhibitors, the BCL-2 inhibitor venetoclax, FLT3 and IDH inhibitors, and hedgehog pathway inhibitors), injectable and oral hypomethylating agents, cytotoxic chemotherapy such as cytarabine, anthracyclines, and liposomal formulations, antibody-drug conjugates and other immunotherapies, cell and gene therapy, and supportive agents.

According to the National Cancer Institute's SEER program, AML remains a disease of older adults with poor outcomes: the median age at diagnosis is 70 years, about 62% of cases occur at age 65 or older, and five-year relative survival stands at 33.4%, with an estimated 22,720 new U.S. cases and 11,500 U.S. deaths expected in 2026. Worldwide, the International Agency for Research on Cancer (IARC) recorded 495,113 new leukemia cases in 2022, nearly half of them in Asia. Spending is led by venetoclax-based therapy: AbbVie reported USD 2,792 million in 2025 worldwide sales of Venclexta, a figure that also covers CLL.

Market Dynamics

The arrival of menin inhibitors is the most important growth driver: the U.S. FDA approved ziftomenib (KOMZIFTI) from Kura Oncology and Kyowa Kirin on 13 November 2025, following Syndax's revumenib (Revuforj), giving the market two approved agents in the class within a year. Venetoclax combined with azacitidine or low-dose cytarabine is now the standard for patients too frail for intensive chemotherapy and forms the base onto which new drugs are added. An aging population, wider sequencing at diagnosis, and regulators' readiness to approve on single-arm data add further support.

The small patient population limits revenue per product, especially when a drug is confined to a relapsed molecular subgroup of a few thousand patients a year. Short response durations and early deaths cut time on therapy, cytarabine, anthracyclines, azacitidine, and decitabine are all generic, so the backbone of most regimens earns little, and limited molecular testing and transplant capacity in Asia, Africa, and Latin America restrict use of targeted drugs where most cases occur. Key challenges include drug sequencing and resistance, toxicity in frail patients, payer scrutiny of costly drugs with modest response rates, and competition for trial patients.

The largest opportunity is the move of menin inhibitors into frontline combinations: the Phase 3 KOMET-017 study of ziftomenib in newly diagnosed patients has enrolled its first patient, and revumenib is being studied as a triplet with azacitidine and venetoclax in untreated patients with NPM1 or KMT2A alterations. Maintenance therapy and MRD-guided treatment, all-oral regimens that can be given in outpatient settings, and emerging markets where diagnostics and reimbursement are expanding offer further growth. Key trends include adding branded targeted agents to a low-cost generic backbone, the shift of care from inpatient wards to community and home settings, the use of molecular and MRD testing as core treatment infrastructure, and partnerships between specialist developers and regional commercial partners.

Segment Analysis

The report analyzes the market by therapy class, mutation target, line of therapy, patient fitness, route of administration, treatment setting, end user, and geography, helping stakeholders identify where treatment value is moving.

By therapy class, the report covers targeted therapy, hypomethylating agents, chemotherapy, immunotherapy & antibody-drug conjugates, cell & gene therapy, and supportive care & adjunct therapy. Targeted therapy is expected to hold the largest share in 2026, as it includes venetoclax, the anchor of lower-intensity treatment, along with FLT3 inhibitors, IDH1 and IDH2 inhibitors, and the new menin inhibitor class, all of which are branded and priced well above the generic backbone. Within targeted therapy, menin inhibitors are expected to grow at the highest CAGR, supported by the two recent U.S. approvals and the advance of both agents into frontline combination trials. Generic hypomethylating agents and chemotherapy carry large volumes but modest revenue.

The mutation target analysis covers mutation-agnostic & broad-spectrum regimens, NPM1-mutated, FLT3-mutated, IDH-mutated, KMT2A-rearranged, TP53-mutated & adverse-risk disease, and other subtypes. Mutation-agnostic and broad-spectrum regimens are expected to account for the largest share in 2026, as venetoclax-based combinations are given to unfit newly diagnosed patients regardless of genotype and chemotherapy is chosen by fitness rather than mutation. NPM1-mutated disease is expected to grow at the highest CAGR, as both approved menin inhibitors carry NPM1 indications and Syndax estimates about 4,500 U.S. patients with relapsed or refractory NPM1-mutated AML each year, with frontline use set to widen this pool.

By line of therapy, the report covers frontline induction & consolidation, maintenance therapy, and relapsed or refractory therapy. Frontline treatment is expected to hold the largest share in 2026, because every newly diagnosed patient receives first-line therapy while only a portion survive to later lines. Maintenance therapy is expected to grow at the highest CAGR, building on the survival benefit already shown by oral hypomethylating maintenance after remission and the testing of targeted drugs after remission and after transplant, with MRD results used to identify patients at highest risk of relapse. New drugs still win first approval in the relapsed or refractory setting.

By patient fitness, the market is divided into patients ineligible and eligible for intensive chemotherapy. Patients ineligible for intensive chemotherapy are expected to account for the largest share in 2026, as most patients are older and have heart, kidney, or performance status limits that rule out cytarabine and anthracycline induction, and instead receive venetoclax with azacitidine, decitabine, or low-dose cytarabine. Patients eligible for intensive chemotherapy are expected to grow at the highest CAGR, as targeted drugs are added to intensive induction and consolidation, as FLT3 inhibitors have already done, and as post-transplant maintenance becomes routine in younger patients.

By route of administration, the report covers oral, intravenous, and subcutaneous products. Oral therapy is expected to hold the largest share in 2026 and to grow at the highest CAGR, since almost every branded drug launched over the past decade is a pill, including venetoclax, FLT3 and IDH inhibitors, both menin inhibitors, and oral hypomethylating products combining decitabine or azacitidine with a cytidine deaminase inhibitor. Oral treatment also suits an older population that tolerates outpatient care better than long hospital stays.

By treatment setting, the report covers outpatient & ambulatory care, inpatient hospital care, and home-based care. Outpatient and ambulatory care is expected to lead in 2026, as venetoclax plus a hypomethylating agent can be given in clinics with transfusion and infection support, together with oral targeted drugs. Home-based care is expected to grow at the highest CAGR, supported by all-oral regimens, specialty pharmacy dispensing, remote toxicity monitoring, telehealth follow-up, and the preference of older patients to stay at home.

The end user analysis includes hospitals & academic cancer centers, specialty hematology & community oncology practices, transplantation centers, specialty pharmacies, and others. Hospitals and academic cancer centers are expected to hold the largest share in 2026, as AML usually presents as an emergency that needs rapid cytogenetic and molecular workup and induction-phase support. Specialty hematology and community oncology practices are expected to grow at the highest CAGR, as oral, lower-intensity regimens can be given closer to home and reference laboratories now return NPM1, KMT2A, FLT3, and IDH results to community prescribers.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, the Nordic countries, Australia & New Zealand, Southeast Asia, and four rest-of-region groups. It considers disease burden, testing and transplant capacity, approval timing, and reimbursement.

North America is expected to hold the largest share of the market in 2026, owing to early regulatory access, broad molecular testing, concentrated transplant capacity, and the highest spending per patient. Both menin inhibitors launched first in the U.S. Europe is expected to rank second, supported by strong academic hematology networks, cooperative trial groups, and transplant capacity, although health technology assessment bodies compare new drugs with a low-cost generic backbone, which slows uptake and makes managed-entry agreements common. Germany, the U.K., France, Italy, and Spain account for most regional value.

Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as it carries the largest disease burden, with IARC data showing nearly half of global leukemia cases occurring in Asia. Growth is supported by expanding molecular testing, the listing of targeted drugs in national reimbursement schemes and volume-based procurement, and more transplant capacity; Japan is the most developed market, while China pairs very large patient numbers with fast domestic development of menin, FLT3, and BCL-2 inhibitors. In Latin America, Brazil leads, followed by Mexico, Argentina, and Colombia, with diagnostic gaps as the main barrier, while in the Middle East & Africa, Gulf states, Israel, and Turkey adopt new drugs relatively quickly but much of Sub-Saharan Africa lacks basic diagnostic capacity.

Competitive Landscape

The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, strategic developments (regulatory approvals and label expansions, launches, partnerships and licensing, acquisitions, trial readouts, and companion diagnostic collaborations), and 2025 market share/rank analysis, with company profiles covering business overview, financials, product portfolio, developments, and SWOT analysis.

The market is moderately consolidated, with large drug makers defending established mechanisms and specialist companies launching first-in-class drugs, often through regional partnerships. AbbVie, with Roche, holds venetoclax; Astellas, Novartis, and Daiichi Sankyo hold FLT3 inhibitors; Servier and Rigel hold IDH inhibitors; Bristol Myers Squibb, Otsuka, and Taiho hold oral hypomethylating products; Pfizer markets an antibody-drug conjugate and Jazz a liposomal chemotherapy; and Syndax, Kura Oncology, and Kyowa Kirin market the menin inhibitors. Johnson & Johnson and Sumitomo Pharma are developing further menin inhibitors, while Teva, Sandoz, Dr. Reddy's, and Hikma supply generic backbone drugs.

Key companies profiled in the report include AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Astellas Pharma Inc. (Japan), Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Servier Laboratories (France), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Jazz Pharmaceuticals plc (Ireland), Syndax Pharmaceuticals, Inc. (U.S.), Kura Oncology, Inc. (U.S.), Kyowa Kirin Co., Ltd. (Japan), Otsuka Pharmaceutical Co., Ltd. (Japan), Taiho Pharmaceutical Co., Ltd. (Japan), Rigel Pharmaceuticals, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz Group AG (Switzerland), Dr. Reddy's Laboratories Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson (U.S.), Sumitomo Pharma Co., Ltd. (Japan), Aptose Biosciences Inc. (Canada), and Immune-Onc Therapeutics, Inc. (U.S.).

How This Report Helps

• Provides reliable market size estimates and long-term forecasts for the global acute myeloid leukemia market through 2036.
• Explains how menin inhibitors, venetoclax-based regimens, and molecular testing are reshaping AML treatment and spending.
• Assesses the impact of small patient pools, short treatment duration, generic backbones, and payer scrutiny on market value.
• Identifies high-growth opportunities across therapy class, mutation target, line of therapy, patient fitness, route, setting, end user, and region.
• Tracks the pipeline across menin, FLT3, IDH, CD123, immunotherapy, and cell therapy programs, including frontline and maintenance trials.
• Benchmarks leading drug makers, specialist developers, and generic suppliers on portfolios, partnerships, and strategy.
• Supports portfolio, development, access, and licensing decisions for drug developers and investors.

Key Questions Answered

• How large is the global acute myeloid leukemia market today, and how will it grow through 2036?
• How will the move of menin inhibitors into frontline combinations change the size and structure of the market?
• What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
• How do the generic chemotherapy and hypomethylating backbone affect pricing and reimbursement of new drugs?
• Which therapy classes, mutation targets, lines of therapy, and care settings will grow the fastest?
• How are molecular diagnostics and MRD testing changing treatment selection and duration?
• Which regions and countries offer the most attractive opportunities as testing and reimbursement expand?
• Who are the leading companies in the market, and how do they compare?
• What approvals, licensing deals, and trial readouts are shaping competition?